BRAF and colorectal cancer: In contrast, resistance to the BRAF inhibitor vemurafenib recurrently selected for a gain of chr7 in the BRAF mutant colorectal cancer cell line Colo205, but for recurrent gains of chr11 and 18 in A375, a BRAF mutant melanoma cell line (Lukow et al. 2021).